Product Description
Glycopyrronium (Qbrexza) topical wipes are labeled for the treatment of hyperhidrosis. Glycopyrronium wipes contain a topically-dosed anticholinergic. When applied to the axillae, they reduce sweating in patients nine years and older with hyperhidrosis (Sourced from: https://www.aafp.org/afp/2019/0915/p372.html)
Mechanisms of Action: M1 Antagonist, M2 Antagonist, M3 Antagonist, M4 Antagonist, M5 Antagonist
Novel Mechanism: No
Modality: Small Molecule
Route of Administration: Oral, Inhalant
FDA Designation: *
Approval Status: Approved
Approved Countries: Argentina | Australia | Austria | Bangladesh | Belgium | Bosnia | Brazil | Bulgaria | Canada | Chile | Colombia | Croatia | Cyprus | Czech | Denmark | Dominican Republic | Ecuador | Egypt | Estonia | European Medicines Agency | Finland | France | Germany | Greece | Hong Kong | Hungary | Iceland | India | Indonesia | Ireland | Israel | Italy | Japan | Jordan | Korea | Latvia | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | Netherlands | New Zealand | Norway | Pakistan | Peru | Philippines | Poland | Portugal | Romania | Russia | Saudi Arabia | Serbia | Singapore | Slovakia | Slovenia | South Africa | Spain | Sri Lanka | Sweden | Switzerland | Taiwan | Thailand | Tunisia | Turkey | Ukraine | United Arab Emirates | United Kingdom | United States | Uruguay | Venezuela | Vietnam
Approved Indications: None
Known Adverse Events: None
Company: Novartis
Company Location: Europe
Company Founding Year: 1996
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Argentina, Austria, Brazil, Bulgaria, Canada, China, Colombia, Czech Republic, Denmark, Finland, France, Germany, Greece, Guatemala, Hungary, India, Italy, Japan, Malaysia, Mexico, Norway, Philippines, Poland, Portugal, Puerto Rico, Romania, Slovakia, South Africa, South Korea, Spain, Sweden, Thailand, United Kingdom, United States, Unknown Location, Vietnam
Active Clinical Trial Count:
Recent & Upcoming Milestones
Highest Development Phases
Phase 3: Anesthesia Related|Asthma|Bradycardia|Chronic Obstructive Pulmonary Disease|Hyperhidrosis
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
CTR20250232 |
CTR20250232 | P3 |
Completed |
Bradycardia|Anesthesia Related |
2025-12-25 |
2026-01-04 |
Patient Enrollment|Primary Completion Date|Study Completion Date|Treatments|Trial Status |
|
NCT05863104 |
GPBK-08/2018 | P2 |
Completed |
Hyperhidrosis |
2024-03-06 |
50% |
2024-04-05 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
NCT05222529 |
CQVM149C2201 | P2 |
Recruiting |
Asthma |
2027-07-30 |
12% |
2025-06-04 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments |
NCT06067828 |
ATHLOS | P3 |
Active, not recruiting |
Chronic Obstructive Pulmonary Disease |
2026-01-30 |
50% |
2025-12-20 |
Patient Enrollment|Primary Endpoints|Treatments|Trial Status |
2021-004972-32 |
Pharmacokinetics, pharmacodynamics, safety and tolerability of glycopyrronium (bromide) in children | P2 |
Active, not recruiting |
Asthma |
2023-12-25 |
12% |
2025-05-22 |
Treatments |
NCT06234345 |
TRIPLAR | P3 |
Not yet recruiting |
Chronic Obstructive Pulmonary Disease |
2028-08-01 |
35% |
2025-02-15 |
Primary Completion Date|Primary Endpoints|Start Date |
2023-507407-59-00 |
D5989C00001 THARROS | P3 |
Recruiting |
Chronic Obstructive Pulmonary Disease |
2028-03-07 |
52% |
2025-05-02 |
|
NCT04320342 |
TRITON | P3 |
Completed |
Chronic Obstructive Pulmonary Disease |
2026-01-12 |
38% |
2026-01-31 |
Primary Endpoints |
CTR20251161 |
CTR20251161 | P3 |
Completed |
Unknown |
2025-10-09 |
2025-11-02 |
Patient Enrollment|Primary Completion Date|Start Date|Study Completion Date|Treatments|Trial Status |
|
2023-506565-57-00 |
D5985C00002 | P3 |
Active, not recruiting |
Chronic Obstructive Pulmonary Disease |
2025-09-05 |
42% |
2025-05-02 |
Treatments |
NCT06075095 |
D5985C00002 | P3 |
Completed |
Chronic Obstructive Pulmonary Disease |
2025-08-12 |
42% |
2025-08-29 |
Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
2023-505787-11-00 |
D5982C00007 | P3 |
Completed |
Asthma |
2025-03-18 |
2025-05-02 |
Treatments |
|
2023-505786-88-00 |
D5982C00008 | P3 |
Completed |
Asthma |
2025-03-19 |
2025-05-02 |
Treatments |
|
2022-001476-33 |
2022-001476-33 | P3 |
Completed |
Chronic Obstructive Pulmonary Disease |
2024-03-26 |
45% |
2025-07-09 |
Treatments |
2019-001762-14 |
Anti-inflammatory effects of Glycopyrronium | P3 |
Active, not recruiting |
Asthma |
2022-07-02 |
2022-03-13 |
Treatments |
|
CTR20252448 |
CTR20252448 | P1 |
Completed |
Anesthesia Related |
2025-10-21 |
2025-11-23 |
||
JapicCTI-194818 |
JapicCTI-194818 | P3 |
Planned |
Hyperhidrosis |
2021-08-31 |
|||
NCT06723756 |
D598AC00001 | P1 |
Completed |
Asthma |
2025-06-01 |
88% |
2025-06-06 |
Primary Completion Date|Primary Endpoints |
CTR20243686 |
CTR20243686 | P2 |
Completed |
Chronic Obstructive Pulmonary Disease |
2025-06-26 |
2025-07-27 |
Patient Enrollment|Primary Completion Date|Study Completion Date|Treatments|Trial Status |
|
2024-511382-11-00 |
CQVM149C2201 | P2 |
Recruiting |
Asthma |
2025-05-31 |
2025-05-02 |
Treatments |